(Source: Actelion Ltd) ALLSCHWIL, SWITZERLAND - 13 May 2015 - Actelion Ltd (SIX: ATLN) today announced that key data from the pivotal Phase III GRIPHON study with the investigational drug selexipag (Uptravi®), will be shared during an oral presentation at the American Thoracic Society (ATS) Conference in Denver, Colorado, USA. The oral presentation covering results from key subgroup populations will be given by Dr. Kelly Chin of the University of Texas Southwestern Medical Center, Dallas, Texas, US at 15.45 on May 17, 2015. The abstract can now be found online here. The ATS Conference will also see the presentation of further information from the macitentan (Opsumit®) Phase III SERAPHIN...
↧